We're building a better ClinicalTrials.gov. Check it out and tell us what you think!

Key Record Dates

ClinicalTrials.gov Identifier: NCT04303169
Brief Title: Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

First Submitted : March 9, 2020
First Submitted that Met QC Criteria : March 9, 2020
First Posted : March 10, 2020

Last Update Submitted that Met QC Criteria : September 15, 2022
Last Update Posted : September 16, 2022